NYLIM
NBIX icon

New York Life Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

New York Life Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.5M Buy
14,832
+444
+3% +$65.9K 0.02% 519
2026
Q1 		$1.9M Buy
14,388
+4,859
+51% +$645K 0.02% 557
2025
Q4 		$1.35M Sell
9,529
-708
-7% -$103K 0.01% 568
2025
Q3 		$1.44M Sell
10,237
-352
-3% -$47.7K 0.01% 597
2025
Q2 		$1.33M Sell
10,589
-403
-4% -$46.2K 0.01% 594
2025
Q1 		$1.22M Sell
10,992
-2
-0% -$253 0.01% 620
2024
Q4 		$1.5M Sell
10,994
-1,688
-13% -$209K 0.01% 594
2024
Q3 		$1.46M Buy
12,682
+437
+4% +$59.9K 0.01% 627
2024
Q2 		$1.69M Buy
12,245
+1,330
+12% +$182K 0.02% 593
2024
Q1 		$1.51M Sell
10,915
-268
-2% -$36.6K 0.02% 600
2023
Q4 		$1.47M Buy
11,183
+315
+3% +$36.3K 0.02% 591
2023
Q3 		$1.22M Buy
10,868
+5,435
+100% +$572K 0.01% 591
2023
Q2 		$512K Buy
+5,433
New +$531K 0.01% 702

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York Life Investment Management's NBIX Position: Q2 2026 in Review

New York Life Investment Management increased its Neurocrine Biosciences (NBIX) stake by 3.1% in Q2 2026, buying an estimated $65.9K and bringing the position to 14,832 shares worth $2.5M. The position accounts for 0.02% of the portfolio, ranked #519.

New York Life Investment Management first reported a position in NBIX in Q2 2023 and has held it in 13 quarters since. 588 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • New York Life Investment Management held 14,832 shares of Neurocrine Biosciences worth $2.5M as of Q2 2026.
  • New York Life Investment Management bought 444 Neurocrine Biosciences shares in Q2 2026, an estimated $65.9K.
  • Neurocrine Biosciences made up 0.02% of New York Life Investment Management's portfolio in Q2 2026, its #519 holding.
  • New York Life Investment Management first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 13 quarters since.
  • 588 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.